Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Biogen, Philips, Lucid Fall Premarket; Ocugen, Didi Global Rise

Published 01/12/2022, 08:03 AM
Updated 01/12/2022, 08:04 AM
© Reuters

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Wednesday, January 12th. Please refresh for updates.

  • Biogen (NASDAQ:BIIB) stock slumped 8.5% after the U.S. government Medicare program said it will require patients it will cover Alzheimer's treatments, including the drugmaker's Aduhelm, to be enrolled in a clinical trial, limiting access to the treatment. Piper Sandler downgraded its stance to “neutral” from “overweight”.

  • Lucid (NASDAQ:LCID) stock fell 1.1% after Chairman Andrew Liveris announced plans to build an electric-vehicle factory in Saudi Arabia by 2025 or 2026.

  • PayPal (NASDAQ:PYPL) stock fell 1.9% after Jefferies downgraded its stance on the digital payments company to “hold” from “buy”, citing the normalizing of consumer conditions and limited catalysts ahead.

  • Philips (NYSE:PHG) ADRs fell 15% after the Dutch maker of medical equipment warned of a hit to its fourth-quarter profit, citing supply chain shortages and customers choosing to delay installation of equipment.

  • Meta Platforms (NASDAQ:FB) stock fell 0.1% despite the Facebook-owner appointing DoorDash (NYSE:DASH) CEO Tony Xu to its board to help advise on its expansion into e-commerce. 

  • Exxon Mobil (NYSE:XOM) stock rose 0.3% after Reuters reported that the oil major put some of its shale assets in Ohio on the block.

  • Didi Global (NYSE:DIDI) ADRs rose 5.1% following a report that the ride-hailing company’s Hong Kong IPO, announced in December, could happen in the second quarter of this year along with its withdrawal from the NYSE.

  • Wells Fargo (NYSE:WFC) stock rose 0.9% after Piper Sandler upgraded its stance on the banking giant to “overweight” from “neutral”, saying the bank should benefit disproportionately from a climate of rising interest rates.

  • Ocugen (NASDAQ:OCGN) stock rose 5.8% after positive results from trials of the biopharmaceutical company’s vaccine candidate Covaxin.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.